Neuropharmacological actions of two new adrenergic beta-receptor antagonists, bunolol and H 64-52.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000498:Allyl Compounds / Q000494:pharmacology; D000605:Amino Alcohols / Q000494:pharmacology*; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D000927:Anticonvulsants; D001522:Behavior, Animal / Q000187:drug effects; D002490:Central Nervous System / Q000187:drug effects; D003864:Depression, Chemical; D005260:Female; D006993:Hypnotics and Sedatives; D002040:Levobunolol / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010424:Pentobarbital / Q000494:pharmacology; D010636:Phenols / Q000494:pharmacology; D011412:Propanolamines; D051381:Rats
D000319:Adrenergic beta-Antagonists; D000498:Allyl Compounds; D000605:Amino Alcohols; D000927:Anticonvulsants; D006993:Hypnotics and Sedatives; D010636:Phenols; D011412:Propanolamines; C001849:H 64-52; D000661:Amphetamine; D002040:Levobunolol; D010424:Pentobarbital